Merxin Ltd and OECHSLERhealth are excited to announce a Strategic Partnership to Establish The SMI Powerhouse to Streamline Soft Mist Inhaler Access for Drug Developers.

Key Benefits for Drug Developers

Through The SMI Powerhouse, Merxin Ltd and OECHSLERhealth will empower inhaled drug developers with faster access to market-ready SMI devices by addressing key enablers. The Strategic Partnership is designed to:

REDUCE TIME TO MARKET

ENHANCE RELIABILITY

WIDEN ACCESS TO SUPERIOR DRUG DELIVERY

OPTIMISE COSTS

Together, Merxin Ltd and OECHSLERhealth will become the leading supplier of SMIs, providing drug developers with a platform to succeed in their markets and to enhance patient outcomes worldwide.

DOWNLOAD THE PRESS RELEASE